Placement of fully covered self-expandable metal stents in patients with locally advanced esophageal cancer before neoadjuvant therapy.
BACKGROUND
Most patients with locally advanced esophageal cancer requiring neoadjuvant therapy have significant dysphagia.


OBJECTIVE
To report our experience in using a fully covered self-expandable metal stent (FCSEMS) to treat malignant dysphagia and for maintenance of nutritional support during neoadjuvant therapy.


METHODS
Retrospective study.


METHODS
Two tertiary-care referral centers.


METHODS
This study involved 55 patients with locally advanced esophageal cancer (50 adenocarcinoma, 5 squamous cell carcinoma). Forty-three patients were men, and the mean age was 65.8 years.


METHODS
EUS followed by FCSEMS placement.


METHODS
Procedural success, dysphagia scores, patient weights, stent migration, and stent-related complications.


RESULTS
All stents were successfully placed. Tumors were located in the middle esophagus (n = 10) and distal esophagus (n = 45). The mean dysphagia score obtained at 1 week after stent placement had improved significantly from baseline (2.4 and 1, respectively; P < .001). Patients maintained their weights at 1 month follow-up when compared with baseline (153 and 149 pounds, respectively; P = .58). Immediate complications included chest discomfort in 13 patients; 2 patients required stent removal because of intractable pain. One patient had stent removal because of significant acid reflux. Stent migration occurred at some point in 17 of 55 patients (31%). There was a delayed perforation in 1 patient. Because of disease progression or the discovery of metastasis after neoadjuvant therapy, only 8 of 55 patients underwent curative surgery.


CONCLUSIONS
Retrospective study.


CONCLUSIONS
Placement of FCSEMSs in patients with locally advanced esophageal cancer significantly improves dysphagia and allows for oral nutrition during neoadjuvant therapy. FCSEMSs appear to be effective for palliating dysphagia. Migration was not associated with injury or harm to the patient and usually represented a positive response to neoadjuvant therapy. Few patients undergoing stenting in this situation ultimately undergo surgery because of disease progression or poor operative candidacy.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
Ali A
AA
Siddiqui
Avik
A
Sarkar
Sara
S
Beltz
Jason
J
Lewis
David
D
Loren
Thomas
T
Kowalski
John
J
Fang
Kristen
K
Hilden
Douglas G
DG
Adler
D000230:Adenocarcinoma / Q000150:complications* / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001835:Body Weight; D002294:Carcinoma, Squamous Cell / Q000150:complications* / Q000473:pathology / Q000628:therapy; D003680:Deglutition Disorders / Q000209:etiology / Q000628:therapy*; D004938:Esophageal Neoplasms / Q000150:complications* / Q000473:pathology / Q000628:therapy; D005260:Female; D005764:Gastroesophageal Reflux / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D010146:Pain / Q000209:etiology; D011475:Prosthesis Failure / Q000209:etiology; D012189:Retrospective Studies; D012720:Severity of Illness Index; D015607:Stents / Q000009:adverse effects